Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Antibodies, Monoclonal

Durvalumab

Immunoglobulins

Immunoglobulin G

Chlorotrianisene

Immunoglobulins, Intravenous

Antineoplastic Agents, Immunological

All patients enrolled with receive the sequential therapy of TACE, ablation and durvalumab.

Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.

TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.

Transcatheter Hepatic Arterial Chemoembolization (TACE)

In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).

Ablation

This is a pilot study with a single arm in a single center assessing safety and efficacy of combination therapy of TACE and ablation and durvalumab. This study will be conducted in selected patients with intermediate stage HCC not amenable to curative therapy.

Approximately 30 patients will be enrolled and receive the following treatments:

TACE (day 1, up to twice. TACE interval will be 4～6 weeks) → Ablation (4 weeks after the last TACE, up to twice. Ablation interval will be 4～6 weeks) → Durvalumab (at least 1 week after the last ablation, 1500 mg Q4W, until mRECIST criteria defined radiological progression or other discontinuation criteria were met, but no more than 1 year).

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

A Single-Arm Open-Label Pilot Study of Combination Therapy of TACE and Ablation With Durvalumab in A Selected Hepatocellular Carcinoma Population at Intermediate Stage

Fudan University

Professor

Spots Global Cancer Trial Database for transcatheter hepatic arterial chemoembolization (tace)